Evidence on SGLT2 Inhibitors' Efficacy in Older and Frail Patients

Area of Science:

• Gerontology
• Pharmacology
• Nephrology

Background:

• Sodium-glucose cotransporter 2 (SGLT2) inhibitors demonstrate significant cardiovascular and nephroprotective effects in randomized-controlled trials (RCTs).
• Older adults are a key demographic for SGLT2 inhibitor therapy due to high prevalence of type 2 diabetes mellitus (T2DM), heart failure (HF), and chronic kidney disease (CKD).
• Clinical trial representation of older adults is limited, failing to capture their heterogeneity, especially concerning frailty.

Purpose of the Study:

• To review and critically evaluate the efficacy of SGLT2 inhibitors in older and frail adult populations.
• To focus on age-specific outcomes including cognitive function, sarcopenia risk, and functional activity.
• To identify current evidence gaps concerning frailty in older adults treated with SGLT2 inhibitors.

Main Methods:

• Systematic review and critical appraisal of existing literature.
• Analysis of randomized-controlled trials (RCTs) and observational studies.
• Focus on studies including older adults, with subgroup analysis for frail individuals.

Main Results:

• SGLT2 inhibitors show promise in improving cardiovascular and renal outcomes in older adults.
• Evidence regarding specific benefits and risks in frail older adults is still emerging.
• Limited data exists on the impact of SGLT2 inhibitors on cognitive function, sarcopenia, and functional status in this population.

Conclusions:

• SGLT2 inhibitors are beneficial for older adults with T2DM, HF, and CKD, but careful consideration of frailty is crucial.
• Further research is essential to understand the nuanced effects of SGLT2 inhibitors in frail older adults.
• Tailoring SGLT2 inhibitor therapy based on multidimensional assessment, including frailty, is recommended for optimal patient outcomes.